Tumor News and Research RSS Feed - Tumor News and Research

Aspirin may help boost effectiveness of cancer treatment

Aspirin may help boost effectiveness of cancer treatment

Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell today (Thursday). [More]
HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States. [More]
Children's Hospital Los Angeles receives $2 million to spur research on brain, spinal cord tumors

Children's Hospital Los Angeles receives $2 million to spur research on brain, spinal cord tumors

A life-changing event for a Los Angeles family has resulted in their funding an endowment to support The Kort Family Foundation Brain and Spinal Cord Tumor Research Program in the Division of Neurosurgery at Children's Hospital Los Angeles. [More]
Imetelstat drug shows promise in treating patients with myelofibrosis

Imetelstat drug shows promise in treating patients with myelofibrosis

Imetelstat, a novel drug that targets telomerase, has demonstrated potential value in treating patients with myelofibrosis, according to the results of a study published today in the New England Journal of Medicine. [More]
Study reveals new epigenetic mechanism underlying progression of cancer tumors

Study reveals new epigenetic mechanism underlying progression of cancer tumors

Aggressive cancer growth and alterations in gene activity without changes in DNA sequence (epigenetics) are associated with mutant p53 proteins, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
TMIGD1 protein could be a novel target for restoring kidney function from kidney disease

TMIGD1 protein could be a novel target for restoring kidney function from kidney disease

A new discovery by Boston University School of Medicine (BUSM) researchers may change how kidney disease is treated in the future. [More]
Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients. [More]
New study suggests potential use of targeted therapies for two subtypes of esophageal cancer

New study suggests potential use of targeted therapies for two subtypes of esophageal cancer

Nearly all advanced esophageal cancers harbor genetic mutations that can be targeted with emerging drug therapies, according to a new study published in The Oncologist on September 2, 2015. [More]
Study reveals presence of new genetic mutation in melanoma cancer cells

Study reveals presence of new genetic mutation in melanoma cancer cells

There is strong evidence that the protein complex APC/C may function as a tumor suppressor in multiple cancers including lymphoma, colorectal and breast cancer, and now melanoma. A new study has revealed that a genetic mutation leading to repression of a specific protein, Cdh1, which interacts with APC/C, is present in melanoma cancer cells. [More]
Incorporating clinical genomic sequencing data into clinical management improves pediatric cancer treatment

Incorporating clinical genomic sequencing data into clinical management improves pediatric cancer treatment

In a study that included children and young adults with relapsed or refractory cancer, incorporation of integrative clinical genomic sequencing data into clinical management was feasible, revealed potentially actionable findings in nearly half of the patients, and was associated with change in treatment and family genetics counseling for a small proportion of patients, according to a study in the September 1 issue of JAMA. [More]
UCLA scientists develop promising new combination treatment for glioblastoma

UCLA scientists develop promising new combination treatment for glioblastoma

UCLA scientists have developed a potentially promising new combination therapy for glioblastoma, the deadliest form of brain cancer. [More]
Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists. [More]
U-M study suggests potential treatment options for children with aggressive, advanced cancer

U-M study suggests potential treatment options for children with aggressive, advanced cancer

For children with rare, aggressive and advanced cancer, precision medicine may help doctors determine their best treatment options, a new study finds. [More]
Treating cancer cells with quizartinib inhibits key metabolic pathway, activates macroautophagy

Treating cancer cells with quizartinib inhibits key metabolic pathway, activates macroautophagy

A study published in The Journal of Cell Biology describes a way to force cancer cells to destroy a key metabolic enzyme they need to survive. [More]
Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study. [More]
Northwestern University receives $11.7 million NCI grant to use nanotechnology for cancer treatments

Northwestern University receives $11.7 million NCI grant to use nanotechnology for cancer treatments

Northwestern University, a leader in cancer nanotechnology research, has received a five-year, $11.7 million grant from the National Cancer Institute to use nanotechnology to develop next-generation cancer treatments. [More]
MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer. [More]
Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body. [More]
Brain tumor is not always the death sentence

Brain tumor is not always the death sentence

Only half of brain cancers actually start in the brain. The rest - as in the case of former president Jimmy Carter - are metastatic tumors from cancer that originated elsewhere in the body. [More]

Synthetic tissue environment enables spatial definition of cancer cells and macrophages

Tumors are notoriously difficult to study in their natural habitat - body tissues - but a new synthetic tissue environment may give cancer researchers the next-best look at tumor growth and behavior. [More]
Advertisement
Advertisement